Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OPGN
OpGen Inc
0.141
-0.0181 (-11.38%)
Volume: 4,176,767
Day Range: 0.1311 - 0.1648
Last Trade Time: 7:59:43 PM EST
Just got to keep buying here......Need some buying pressure....Very, Very Thin
Starting back up.....very bullish from here....
Gap Filled. Ready to Pop. About to make a Huge Move back up. Sold off after Massive Run Up yesterday
vell looks like the opgn $$ vent to pbla and now exiting ...where is it going next?
OPGN: YEP!! Just like I did, too. (And right now, this is down yet another 22% just before today's Open.) And as I noted yesterday, it appears that Urinary Tract Infections just ain't "TRENDING" these days.
AMAM Tomorrow BRO all the way!!!!
Ya, I dumped as well when I seen it struggle at .40
OPGN: This typical ONE-DAY-WONDER medical crap stock could NOT hold $0.40; then could NOT hold $0.30; & will likely NOT hold even $0.20 before this Close today.
OPGN: Last call for a classic, "DEAD-CAT-BOUNCE"!!! (Enter Promo Code, "Dead Cat".)
OPGN: Yep, but likely 3-yrs., or so, from now. Today, though, this shit can't even hold $0.30. (I dumped hours ago; pathetic!!! May even Close RED today!!)
I believe when this gets FDA approval than you will see lift-off IMO
OPGN: Full-blown TOILET FLUSH!!! (Urinary Track testing, drugs, etc., just ain't "TRENDING"!!!)
OPGN: Heavy resistance at $0.40 here; if can bust-thru-that, well, maybe get a circa 400%-UP run here today --- but increasingly HARD to do such these days. I think we need iHub's legendary "Garyst" here right now!! To scream-out his CLASSIC:
"It's SOARING!!! Get in!!! I am PLEADING with you!!! GET IN NOW!!!"
OPGN: O.K., Emperor BILL!!!
Ok Guy, Next Time!!!!
OPGJ: You gots-me-laughin' hard, right now, Bro!! WHY?? Because I'm on a HOME DEPOT free WiFi, here in San Diego, which BLOCKS all attempts to get GIF's!! And, I had DELETED all of my 'boilerplate' GIF's --- which were already PRE-LOADED for launch anywhere on the iHub website. So, NO FUN right now with my usual GIF's routine.
OPGN: Hey, King EZ!!! WHERE did you buy your latest 'Markets-Crystal-Ball-Scanner' stock picker gadget, Dude??? Enquiring minds need to know???!!!
Invest where's the Cannons for Lord EZZZ
i add to streetmeet stok momentum vatch last veek
OPGN: Absolutely RIGHT, Lord EZ!! (Boy, the Markets have been dishing-it-UP the past couple weeks!!!!)
$OPGN: OHhhhhhhhhh yaaaaaaaaaaaa now 0.37
HELLUVA killer move right ???
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170679825
GO $OPGN
OPGN: Lookin' pretty decent right now, Admiral Mick!!
OPGN: News today looks pretty impressive --- I (myself) get chronic UTI's for decades!! (Up 88% as I speak.)
$OPGN: BOooommmmmmmm......... from 0.12 to now 0.27 !!!!!!!!!
Whatta morning already.
https://www.globenewswire.com/news-release/2022/12/13/2572596/35690/en/OpGen-Announces-Positive-Top-Line-Data-from-Clinical-Trial-for-Unyvero-Urinary-Tract-Infection-Panel.html
Baggers ABOUND
GO $OPGN
******************************************************************************************
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
December 13, 2022 07:30 ET | Source: OpGen, Inc.
...
Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sites
Primary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall weighted average specificity of 97.4% in preliminary analysis
Clinical performance results will be used to prepare submission package for FDA De Novo request
ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced top line data from its successfully completed Unyvero UTI clinical trial. OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens. The test aims at quantitative detection of microorganisms.
The trial was designed to compare the performance of the Unyvero UTI Panel for detecting urinary tract infections (UTI), using clean-catch or catheter related urine samples. Preliminary analysis of all prospectively enrolled samples showed that the primary study endpoint was successfully met by demonstrating an overall weighted average sensitivity of 96.4% and overall weighted average specificity of 97.4% when compared against each trial site’s standard of care microbiology results. These findings are also in line with the interim analysis performed during the first part of the trial.
The trial included a total of 1,858 prospective and archived samples and has run over 3,300 Unyvero cartridges, including controls and reproducibility tests performed at the different trial sites. In addition to local microbiology laboratory results and additional standardized central microbiology data from an independent reference laboratory, OpGen is currently generating next-generation sequencing (NGS) data at its Rockville, MD, lab facility to also allow genotypic correlation of antibiotic resistance markers detected during the study. Based on the results of the unblinded data set, testing of additional contrived samples with well-characterized pathogen strains will complement and provide additional data points for low prevalence strains and antibiotic resistance markers. Based on all the data generated and analyzed, OpGen will now start preparing a De Novo request package for submission to the U.S. FDA in due course.
“Having completed the study as planned, we have successfully generated a large and very comprehensive study data set with multiple reference methods. We’d like to thank our study sites for their contributions in generating these data.”, said Johannes Bacher, Chief Operating Officer of OpGen. “Now that we have unblinded the results, we are excited to proceed with our in-depth analysis and compile the data submission to the FDA over the next few months.”
"Urinary tract infections represent a major healthcare burden, and diagnosing complicated UTI remains challenging. Microbiological cultures take several days to provide definitive results. Pathogenic microbial species may not be detected due to prolonged exposure to antibiotics, and complex polymicrobial infections may be difficult to elucidate. The Unyvero UTI Panel is a new and promising multiplex molecular test for the rapid detection of a comprehensive range of pathogenic bacteria, fungi, and their associated resistance markers directly from urine in under five hours. Rapid results enable early diagnosis and effective antibiotic therapy to help prevent serious complications in UTI patients," said Dr. Christopher Emery, Associate Director of Clinical Microbiology, Indiana University Health Pathology Laboratory (IUHPL), Indianapolis, IN.
OpGen intends to present data from the study at a future conference as well as to submit for a peer reviewed publication.
Disclaimer
Caution - Investigational Device, Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute or imply an offer to sell or transfer any product. Performance characteristics for this device have not yet been established and the U.S. FDA has not yet cleared the panel.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding preliminary analysis and top-line data from OpGen’s clinical trial for its Unyvero Urinary Tract Infection Panel. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com
OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com
OPGN
OpGen Inc
0.194
0.004 (2.11%)
Volume: 388,607
Day Range: 0.18 - 0.20
Bid: 0.1535
Ask: 0.2271
Last Trade Time: 6:14:36 PM EDT
Total Trades: 622
OPGN Detailed Quote
OPGN
OpGen Inc
0.194
0.004 (2.11%)
Volume: 388,607
Day Range: 0.18 - 0.20
Bid: 0.1535
Ask: 0.2271
Last Trade Time: 6:14:36 PM EDT
Total Trades: 622
OPGN Detailed Quote
OPGN
OpGen Inc
0.47
-0.0099 (-2.06%)
Volume: 132,034
Day Range: 0.46 - 0.4825
Bid: 0.46
Ask: 0.47
Last Trade Time: 5:07:39 PM EDT
Total Trades: 254
OPGN Detailed Quote
OPGN
OpGen Inc
0.47
-0.0099 (-2.06%)
Volume: 132,034
Day Range: 0.46 - 0.4825
Bid: 0.46
Ask: 0.47
Last Trade Time: 5:07:39 PM EDT
Total Trades: 254
OPGN Detailed Quote
OPGN
OpGen Inc
0.55
0.00 (0.00%)
Volume: 62,927
Day Range: 0.54 - 0.567999
Bid: 0.55
Ask: 0.5695
Last Trade Time: 7:01:37 PM EDT
Total Trades: 341
OPGN Detailed Quote
OpGen Inc (OPGN)
0.6195 ? -0.0066 (-1.05%)
Volume: 348,510 @06/03/22 6:33:31 PM EDT
Bid Ask Day's Range
0.6 0.64 0.5907 - 0.655
OPGN Detailed Quote
Ollie&Co., retail are on to your game. None dare call your machinations a racket what with forward statements that age like days-old fish in an open air market.
"You can't fool all of the people all of the time." -Abraham Lincoln
OpGen, Inc.
Directors
William E. Rhodes, III 68 Chairman of the Board of Directors
Mario Crovetto 69 Director
R. Donald Elsey 69 Director
Prabhavathi Fernandes, Ph.D. 73 Director
Oliver Schacht, Ph.D. 51 Chief Executive Officer and Director
Other Executive Officers
Albert Weber 58 Chief Financial Officer and Corporate Secretary
Johannes Bacher 53 Chief Operating Officer
https://www.stocksplithistory.com/?symbol=OPGN
$OPGN
Schacht's repeat record of 99% retail losses. Olllie & his clique continually spell doom for retail share buyers. Dollars are vacuumed up for the oversized salaries of top dogs--rewarding abysmal performance. Corporate profligacy and generous perks can be buried in unduly large SG&A expenditures (Selling, General & Administrative).
If Schacht sells the company, he's off the OPGEN gravy train.Then why would he ever voluntarily sell? Total Insider Ownership of shares is only 1.70%, a pittance of shares. (Fintel)
Bottom line for supersized Ollie: Ollie has done and will do whatever is best for Ollie and his little clique. Retail are merely cash cows, nuisances to be exploited. The abominable record of Oliver Schacht, his team, and the BOD and their consistent contempt for retail speaks for itself. Vote accordingly.
A history of repeatedly soaking retail.
$OPGN
ALL SHAREHOLDERS make sure you have put in your votes to VOTE NO FOR R/S AND VOTE NO FOR ALL BOARD OF DIRECTORS
and pass the message along to all other fellow shareholders you are in contact with
….while there is still time to do something about this situation
if BOD are out we can still save our investment, they no longer have the power to wipe out our investment
VOTING IS YOUR RIGHT, VOTING IS YOUR POWER
Most people should have received a link in their email from their broker to vote. Double check and make sure you put your NO Votes in.
It Takes a Pillage--suggested movie title of OPGN managerial/BOD retail ripoff if the account were made into a cinematic feature.
"It Takes a Pillage" tells of a 7-year high-toned shearing of retail investors whereby fuzzy Wall Street and top-tier gymnastics turn $10,000 worth of OPGN shares bought in 2015 into $2.00, all totaled, in 2022 -- all the while fattening the top tier into obesity as retail tighten their belts.
Purely by coincidence, an actor named Olli Schacht played a cyclist in the 1992 German film "Psycho: Das Geheimnis des Phantom-Killers"
https://www.imdb.com/title/tt8892156/
"Olli Schacht is an actor known for "Psycho: Das Geheimnis des Phantom-Killers" (1992) [Translation- "Psycho: The Secret of the Phantom Killer"]
https://www.imdb.com/name/nm10071387/
$OPGN
OpGen Inc (OPGN)
0.53 ? -0.014 (-2.57%)
Volume: 303,183 @04/29/22 6:36:13 PM EDT
Bid Ask Day's Range
0.51 0.549 0.51 - 0.588899
OPGN Detailed Quote
$10,000 invested 2015 would be $2.30 today. Chart below.
Would Madoff be proud of Jones, Ollie Schacht, Rhodes, Bacher, and BOD?
OpGen Directors
William E. Rhodes, III 68 Chairman of the Board of Directors
Mario Crovetto 69 Director
R. Donald Elsey 69 Director
Prabhavathi Fernandes, Ph.D. 73 Director
Oliver Schacht, Ph.D. 51 Chief Executive Officer and Director
Other OpGen Executive Officers
Albert Weber 58 Chief Financial Officer and Corporate Secretary
Johannes Bacher 53 Chief Operating Officer
Ollie won't sell OPGN; no more milllion$ salary on average per annum. Insider ownership is a mere
1.70% (Fintel). The real money is in hefty salaries for top tier management and BOD. If they sell the firm, their gravy train is derailed. Ollie is the visible ringleader & engineer to keep their salaried gravy train on track and running. Three reverse splits in four years (the third is proposed) have kept them nicely housed in upscale neighborhoods and, given the expansionary CEO, very well fed indeed, not to mention sleeping soundly after counting shareholder cash cows.
OPGN Reverse Splits (R/S) history.
01/19/2018 1 for 25
08/29/2019 1 for 20
Proposed 04/14/2022 1 for 5 up to 1 for 20
04-14-2022 "Reverse Stock Split. A vote to approve the adoption of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio not less than five-to-one and not more than twenty-to-one, or the 'Reverse Stock Split,' such ratio and the implementation and timing of such Reverse Stock Split to be determined in the discretion of our Board of Directors (the 'Reverse Stock Split Proposal');
Proxy vote info here. Voting NO sends a strong message of no confidence and lays groundwork for further shareholder action in respect to comportment of the B.O.D. including CEO Ollie Schacht and Chairman Bill Rhodes. OpGen biotechnology, patents, and ARESdb (Ares database) are worth XX scores of millions of dollars in a buyout or takeover. However, the B.O.D. and upper management, overcompensated to the hilt, have failed their shareholders, miserably so. The gang directing this show are unmitigated disasters and undeserving of election much less compensation. For what? 50 cents a share? Send these leeches and non-performers packing.
$OPGN Shareholders of record date 14 April 2022 can vote. 1 share = 1 vote.
The presence in person or by proxy of the holders of thirty four percent (34%) of the outstanding common stock is necessary to constitute a quorum at the Annual Meeting. As of the record date of April 14, 2022, there were 46,557,750 shares of our common stock outstanding, representing the same number of votes. Accordingly, 23,278,876 shares of our common stock will be required to establish a quorum. Abstentions and broker non-votes, if any, are counted as present for determining the presence of a quorum. .
https://www.shareholdereducation.com/proxy-voting-frequently-asked-questions
https://fintel.io/doc/sec-opgen-inc-1293818-def-14a-2022-april-25-19107-1229
NO to All Proposal 1: Election of Directors. The nominees for election as directors at the Annual Meeting will be elected by the vote of a plurality of the shares of our common stock entitled to vote on the election, represented in person or by proxy at the Annual Meeting. This means the director nominees receiving the highest number of affirmative votes will be elected as directors. Votes withheld from a director nominee will have no effect on the election of the director from whom votes are withheld.
NO Proposal 2: Approval of Reverse Stock Split Proposal. Pursuant to our Certificate, the reverse stock split proposal requires the affirmative vote of at least a majority of the outstanding shares of common stock of the Company.
NO Proposal 3: Ratification of CohnReznick's Appointment. The ratification of the appointment of CohnReznick as our independent registered public accounting firm for the 2022 fiscal year requires the affirmative vote of a majority of the votes cast by all stockholders present in person or represented by proxy at the Annual Meeting and entitled to vote on the proposal. If the selection of CohnReznick as our independent registered public accounting firm is not ratified, the Audit Committee of the Board may reconsider its selection.
Proposal 4: Adjournment. The approval of the adjournment requires the affirmative vote of a majority of the votes cast by all stockholders present in person or represented by proxy at the Annual Meeting and entitled to vote on the proposal.
Directors
NO William E. Rhodes, III 68 Chairman of the Board of Directors
NO Mario Crovetto 69 Director
NO R. Donald Elsey 69 Director
NO Prabhavathi Fernandes, Ph.D. 73 Director
NO Oliver Schacht, Ph.D. 51 Chief Executive Officer and Director
Other Executive Officers
NO Albert Weber 58 Chief Financial Officer and Corporate Secretary
NO Johannes Bacher 53 Chief Operating Officer
$OPGN Ollie Schacht is through. The Big Boys are biding their time, will scarf this up, and kick Ollie to the curb.
Cutting edge, genius biotechnologies, but the wrong person as CEO? At this point, if Schacht resigned, most retail shareholders would likely celebrate. Arguably, his departure would open the door to many buyers who also perceive Shacht, with no science background, as a liability if not a leech. Calls by dissatisfied shareholders for his resignation are mushrooming across cyberspace. Opgen, the 3-in-1 company (Curetis, Ares Genetics, OpGen, Inc.) is worth many, many millions, but its premium value has not been unlocked by this rather self-serving glib CEO who lives apart from hoi poloi in insulated luxury courtesy of stockholders. Over a million dollars per year compensation quite undeserved.
1) On Wednesday 01 April 2020, Schacht took over the reins from CEO Evan Jones. On 31 March 2020, OPGN shares closed at $2.55 with a high of $2.70. Market cap on April 3, 2020 was $35.95MM.
2) Three years later, 25 April 2022, OPGN share price stands at US$0.605; market cap US$29.8MM.
3) If CEO performance were judged by those metrics, Schacht is not only a failure, but a pariah whose 2020 compensation package totaled US$1,121,158 (twice that of former CEO Evan Jones).
Don't forget to vote before the upcoming meeting of shareholders.
$OPGN Tweets more cutting-edge biotech from Ares Genetics: ARESid
April 25, 2022
ARESid
Optimized for Pathogen ID and Microbiome Profiling
Detection of bacterial and fungal pathogens via amplicon sequencing can positively impact patient management, particularly for suspected infections with culture-negative samples. (!) (Very big development.)
.
Actionable pathogen ID and microbiome profiling. Read all about it.
https://www.opgen.com/ares/ares-products-services/aresid/
How Sandoz chess move affirms OPGN Ares Genetics are crown jewels ripe for takeover.
A takeover, friendly or hostile, to acquire OpGen for the sake of Ares Genetics isn't just likely, it's virtually inevitable in today's highly acquisitive and combative Dx space.
Why? In short, Ares Genetics holds a unique "key" in overcoming AMR and extending the lifetime of disease-fighting, life-saving antibiotics.
Sandoz CEO said so in 6 April 2022 PR: "As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat. This collaboration (w/OPGN sub Ares Genetics) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets. [i.e., ARESdb + Ares Gen's proprietary digital AI powered DNA testing]."
Keys
1) (ARESdb, ARES data base) OpGen's wholly owned sub Ares Genetics owns the world's largest and most comprehensive data base of genetic antibiotic resistance markers and predictive AMR panels. Continually updated, ARESdb covers an astonishing 30 years of emerging antibiotic resistance to accurately detect AMR.
2) Isolates: The ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally.
3) ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with up to more than 98%.
4) ARES Platform - Proprietary digital health platform combines NGS-based Universal Pathogenome Assay (ARESupa) with cloud based decision support & reporting system (AREScds) that is sustainably keeping pace with rapidly evolving AMR based on an Artificial Intelligence powered in-vitro diagnostics (IVD) Reference Database (ARESdb).
5) ARESupa - Universal Pathogenome Assay (UPA) for any patient sample.
6) AREScds - Secure & HIPAA compliant cloud-based Clinical Decision Support system (CDS) linking AMR markers to treatment response.
7) Ares Gen's proprietary digital AI powered DNA testing.
In short, Ares Genetics is worth a king's ransom.
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
https://finance.yahoo.com/news/opgen-subsidiary-ares-genetics-provides-113000156.html
$NVS $MRK $QGEN
$OPGN They're buying. April 22, 2022 Arete Wealth Advisors LLC purchased a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the medical research company’s stock, valued at approximately $54,000.
Recently, several other hedge funds have also added to their stakes in OPGN.
Why are they buying? There's only one reason to buy.
Millennium Management LLC purchased a new position in shares of OpGen in the 2nd quarter valued at approximately $80,000.
Bank of New York Mellon Corp raised its position in shares of OpGen by 229.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 40,559 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 28,242 shares during the last quarter.
Dimensional Fund Advisors LP purchased a new position in shares of OpGen in the 3rd quarter valued at approximately $154,000.
Citadel Advisors LLC raised its position in shares of OpGen by 46.7% in the 3rd quarter. Citadel Advisors LLC now owns 56,825 shares of the medical research company’s stock valued at $164,000 after purchasing an additional 18,090 shares during the last quarter.
Renaissance Technologies LLC raised its position in shares of OpGen by 74.6% in the 3rd quarter. Renaissance Technologies LLC now owns 151,500 shares of the medical research company’s stock valued at $436,000 after purchasing an additional 64,747 shares during the last quarter.
7.74% of the stock is owned by institutional investors and hedge funds.
https://finnewslive.com/2022/04/22/arete-wealth-advisors-llc-purchases-shares-of-50000-opgen-inc-nasdaqopgn.html
OpGen partners $NVS $MRK $QGEN
$OPGN Why is bioMérieux's acquisition bullish for OpGen? There are meaningful parallels, perhaps foreshadowings, as they relate to OpGen's collaborators such as Sandoz, Merck, et alii.
French firm bioMérieux (2021 revenue US$3.82B) is an in vitro diagnostics biotechnology firm whose history traces back to Louis Pasteur. April 12, 2022: bioMérieux announces agreement to acquire Specific Diagnostics (SD), private U.S. based firm, developer of rapid antimicrobial susceptibility test (AST) system delivering phenotypic AST directly from positive blood cultures.(Note: SD system CE marked; not US-FDA approved; RUO) bioMérieux CEO says their 'acquisition reinforces commitment to sustain antibiotic efficacy for future generations.'
The CEO Richard Sayno of Sandoz, world's leading provider of generic antibiotics, said much the same thing about Sandoz's "key" collaboration with OpGen --except he knows, as is evident by his remarks, that OpGen biotech scores more points than Specific Diagnostics' AST given OpGen's far more robust system, FDA Approved, and AI-powered bioinformatics solutions for antibiotic response prediction, to boot.
Sandoz CEO Richard Saynor stated, “Antibiotics are the cornerstone of modern medicine. AMR, which is now estimated to directly account for nearly 1.3 million deaths worldwide every year, is an unprecedented threat to global public health. As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat. This collaboration (w/OpGen sub) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets. By combining our respective skillsets, we believe we can not only use diagnostic and surveillance data to help healthcare professionals make better diagnoses, but also expand our options to treat AMR in the future, by targeted repurposing of key antibiotics. Our ultimate goal is both simple and radical: to ensure we get the right medicine to the right patient at the right time.”
https://www.globenewswire.com/news-release/2022/04/06/2417469/35690/en/OpGen-s-subsidiary-Ares-Genetics-provides-update-on-collaboration-agreement-to-drive-cutting-edge-digital-solutions-in-global-fight-against-antimicrobial-resistance-AMR.html
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2720
|
Created
|
07/29/15
|
Type
|
Free
|
Moderators |
Vexing problems oftimes lead to creative solutions. OpGen's robust ingenuity is a case in point.
Problem: "Antibiotic resistance is a global threat. There is no system in place to track antibiotic resistance globally. Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats." -U.S. Center for Disease Control
Enter OpGen, Inc. Press Releases
OpGen, Inc. (Gaithersburg, MD, USA) (Nasdaq OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to guide clinicians with rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDRO). Subsidiaries include Curetis GmbH and
Ares Genetics GmbH*. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI. Learn more
OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, PNA FISH, Quick Fish, Acuitas® Lighthouse, and the ARES Technology Platform. The Ares Technology Platform includes ARESdb (db=database) that uses NGS (next generation sequencing) technology and AI-powered bioinformatics solutions to predict antibiotic response (resistance). Artificial intelligence based DNA testing revolutionizes infectious disease diagnostics and therapeutics.* Patient outcomes improved; costs reduced. Learn more
"Time is of the essence in cases of severe infections, not infrequently a question of life or death, and knowing what not to prescribe is as important as knowing what to prescribe."
OpGen Corporate Overview 06-Oct-2020 (Recommended viewing)
*02Oct2020 OpGen's wholly owned Ares Genetics GmbH* (Vienna) won the Austria State Prize for innovation with their Project "ARESupa- Molecular Antibiotic Resistance Diagnostics using Artificial Intelligence - With a (Ares Genetics) universal pathogen test, antibiotic resistance from germs can be predicted quickly and accurately."
OpGen subsidiary Ares Genetics, which combines Next Generation Sequencing (NGS) with ARESdb, is the world‘s most comprehensive database on the genetics of antibiotic resistance. ARESdb is also the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels. ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally. ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with ~98% accuracy. ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR and combines deep whole-genome sequencing data with antibiotic resistance profiles continuously expanded. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI.
Fast & Simple Syndromic Testing for Severe Infections -- Improving Patient Outcomes
Detects pathogens rapidly, including associated antibiotic resistance genes
Antibiotic resistant microorganisms are a global health threat (Per CDC, WHO, US GAO)
Our UNYVERO A50 IS FDA APPROVED UNYVERO FLYER (Recommended viewing)
With the Unyvero A50 Solution, OPGen's wholly owned subsidiary Curetis has developed a molecular diagnostics system for reliable and extremely rapid diagnosis of severe infectious diseases in under 5 hours versus up to 96 hours using current methods. The system uses powerful multiplex PCR technology and syndromic testing to detect a wide variety of microorganisms, antibiotic resistance markers, or toxins.
Unyvero A50 Applications for Major Infectious Disease
HPN- Hospitalized Pneumonia
HPN Solution
BCU — Blood Culture
Analyzes the DNA of 103 pathogens & resistance genes from a
positive blood culture for fast diagnostics of blood stream infections.
BCU Solution
IAI — Intra-Abdominal Infection
IAI Solution
UTI — Urinary Tract Infection
Unyvero A50 System
Unyvero A50 Cartridge
Applications
Unyvero A30 RQ in development
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |